{"search_session":{},"preferences":{"l":"en","queryLanguage":"en"},"patentId":"US_8333965_B2","frontPageModel":{"patentViewModel":{"ref":{"entityRefType":"PATENT","entityRefId":"128-827-329-372-975"},"entityMetadata":{"linkedIds":{"empty":true},"tags":[],"collections":[{"id":10767,"type":"PATENT","title":"Karolinska Institute - Patent Portfolio","description":"","access":"OPEN_ACCESS","displayAvatar":true,"attested":false,"itemCount":1276,"tags":[],"user":{"id":91044780,"username":"Cambialens","firstName":"","lastName":"","created":"2015-05-04T00:55:26.000Z","displayName":"Cambialens","preferences":"{\"usage\":\"public\",\"beta\":false}","accountType":"PERSONAL","isOauthOnly":false},"notes":[{"id":8239,"type":"COLLECTION","user":{"id":91044780,"username":"Cambialens","firstName":"","lastName":"","created":"2015-05-04T00:55:26.000Z","displayName":"Cambialens","preferences":"{\"usage\":\"public\",\"beta\":false}","accountType":"PERSONAL","isOauthOnly":false},"text":"
Search Applicants and Owners separately:\"Karolinska Instit*\"; \"Karolinska inst*\"; \"inst* Karol*\".
Select more for logical variants. Add to collection. Select all patents in the collection and expand by simple families. Add to collection. Total patents: 701
Search Applicants and Owners separately: univ* aberdeen. Select more for logical variants. Add to collection. Select all patents in the collection and expand by simple families. Add to collection. Total patents: 1658
Search Applicants and Owners separately:\"Karolinska Instit*\"; \"Karolinska inst*\"; \"inst* Karol*\".
Select more for logical variants. Add to collection. Select all patents in the collection and expand by simple families. Add to collection. Total patents: 701
Search Applicants and Owners separately: univ* aberdeen. Select more for logical variants. Add to collection. Select all patents in the collection and expand by simple families. Add to collection. Total patents: 1658
a) an anti-interferon alpha antibody produced by the hybridoma deposited with the ATCC as Accession No. PTA-6557;\n
b) a humanized antibody that is a humanized form of the anti-interferon alpha antibody produced by the hybridoma deposited with the ATCC as Accession No. PTA-6557;\n
c) a humanized antibody that is a humanized form of the antibody ACO-1;\n
d) a humanized antibody that is an antibody fragment of a humanized form of the anti-interferon alpha antibody produced by the hybridoma deposited with the ATCC as Accession No. PTA-6557, wherein the antibody fragment specifically neutralizes a bioactivity of at least ten interferon alpha protein subtypes selected from the group consisting of IFNα protein subtypes A, 2, B2, C, F, G, H2, I, J1, K, 4a, 4b and WA, but does not significantly neutralize said bioactivity of IFNα protein subtype D, wherein said bioactivity is activation of the MxA promoter or antiviral activity;\n
e) the humanized antibody of (d) that is an Fab, Fab′, F(ab′)2, Fv or sFv fragment;\n
f) an antibody comprising at least one light chain that comprises the CDRs:\n\nVL1 having the amino acid sequence of SEQ ID NO:12;\nVL2 having the amino acid sequence of SEQ ID NO:14; and\nVL3 having the amino acid sequence of SEQ ID NO:16; and\n
at least one heavy chain that comprises the CDRs:\n\nVH1 having the amino acid sequence of SEQ ID NO:4;\nVH2 having the amino acid sequence of SEQ ID NO:6;\nVH3 having the amino acid sequence of SEQ ID NO:8; and\n
g) the antibody of any of (a) through (f) that is an IgG4 isotype antibody,\n
wherein said disease or condition is selected from the group consisting of Systemic Lupus Erythematosus (SLE), type 1 diabetes, and psoriasis, and whereby at least one symptom of said disease or condition is treated or ameliorated."],"number":1,"annotation":false,"title":false,"claim":true},{"lines":["The method of claim 1, wherein the disease is SLE."],"number":2,"annotation":false,"title":false,"claim":true},{"lines":["The method of claim 1, wherein the disease is psoriasis."],"number":3,"annotation":false,"title":false,"claim":true},{"lines":["The method of claim 1, wherein the antibody is a humanized antibody that is a humanized form of the anti-interferon alpha antibody produced by the hybridoma deposited with the ATCC as Accession No. PTA-6557."],"number":4,"annotation":false,"title":false,"claim":true},{"lines":["The method of claim 1, wherein the antibody is a humanized antibody that is a humanized form of the antibody ACO-1."],"number":5,"annotation":false,"title":false,"claim":true},{"lines":["A method of neutralizing at least one IFNα protein subtype in the blood of a subject, wherein the IFNα protein subtype is selected from the group consisting of protein subtypes A, 2, B2, C, F, G, H2, I, J1, K, 4a, 4b and WA, and wherein said method comprises administering to said subject an effective amount of an antibody selected from the group consisting of:\n
a) an anti-interferon alpha antibody produced by the hybridoma deposited with the ATCC as Accession No. PTA-6557;\n
b) a humanized antibody that is a humanized form of the anti-interferon alpha antibody produced by the hybridoma deposited with the ATCC as Accession No. PTA-6557;\n
c) a humanized antibody that is a humanized form of the antibody ACO-1;\n
d) a humanized antibody that is an antibody fragment of a humanized form of the anti-interferon alpha antibody produced by the hybridoma deposited with the ATCC as Accession No. PTA-6557, wherein the antibody fragment specifically neutralizes a bioactivity of at least ten interferon alpha protein subtypes selected from the group consisting of IFNα protein subtypes A, 2, B2, C, F, G, H2, I, J1, K, 4a, 4b and WA, but does not significantly neutralize said bioactivity of IFNα protein subtype D, wherein said bioactivity is activation of the MxA promoter or antiviral activity;\n
e) the humanized antibody of (d) that is an Fab, Fab′, F(ab′)2, Fv or sFv fragment;\n
f) an antibody comprising at least one light chain that comprises the CDRs:\n\nVL1 having the amino acid sequence of SEQ ID NO:12;\nVL2 having the amino acid sequence of SEQ ID NO:14; and\nVL3 having the amino acid sequence of SEQ ID NO:16; and\n
at least one heavy chain that comprises the CDRs:\n\nVH1 having the amino acid sequence of SEQ ID NO:4;\nVH2 having the amino acid sequence of SEQ ID NO:6;\nVH3 having the amino acid sequence of SEQ ID NO:8; and\n
g) the antibody of any of (a) through (f) that is an IgG4 isotype antibody,\n
wherein said subject has a disease or condition selected from the group consisting of Systemic Lupus Erythematosus (SLE), type 1 diabetes, AIDS; and psoriasis, and wherein at least one IFNα protein subtype in the blood of said subject is neutralized."],"number":6,"annotation":false,"title":false,"claim":true},{"lines":["The method of claim 6, wherein said subject has SLE."],"number":7,"annotation":false,"title":false,"claim":true},{"lines":["The method of claim 6, wherein said subject has psoriasis."],"number":8,"annotation":false,"title":false,"claim":true},{"lines":["The method of claim 6, wherein the antibody is a humanized antibody that is a humanized form of the anti-interferon alpha antibody produced by the hybridoma deposited with the ATCC as Accession No. PTA-6557."],"number":9,"annotation":false,"title":false,"claim":true},{"lines":["The method of claim 6, wherein the antibody is a humanized antibody that is a humanized form of the antibody ACO-1."],"number":10,"annotation":false,"title":false,"claim":true},{"lines":["The method of claim 1, wherein the disease is type 1 diabetes."],"number":11,"annotation":false,"title":false,"claim":true},{"lines":["The method of claim 6, wherein said subject has type 1 diabetes."],"number":12,"annotation":false,"title":false,"claim":true}]}},"filters":{"npl":[],"notNpl":[],"applicant":[],"notApplicant":[],"inventor":[],"notInventor":[],"owner":[],"notOwner":[],"tags":[],"dates":[],"types":[],"notTypes":[],"j":[],"notJ":[],"fj":[],"notFj":[],"classIpcr":[],"notClassIpcr":[],"classNat":[],"notClassNat":[],"classCpc":[],"notClassCpc":[],"so":[],"notSo":[],"sat":[]},"sequenceFilters":{"s":"SEQIDNO","d":"ASCENDING","p":0,"n":10,"sp":[],"si":[],"len":[],"t":[],"loc":[]}}